1
|
Ng B, Viswanathan S, Widjaja AA, Lim WW, Shekeran SG, Goh JWT, Tan J, Kuthubudeen F, Lim SY, Xie C, Schafer S, Adami E, Cook SA. IL11 Activates Pancreatic Stellate Cells and Causes Pancreatic Inflammation, Fibrosis and Atrophy in a Mouse Model of Pancreatitis. Int J Mol Sci 2022; 23:ijms23073549. [PMID: 35408908 PMCID: PMC8999048 DOI: 10.3390/ijms23073549] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 03/14/2022] [Accepted: 03/22/2022] [Indexed: 02/06/2023] Open
Abstract
Interleukin-11 (IL11) is important for fibrosis and inflammation, but its role in the pancreas is unclear. In pancreatitis, fibrosis, inflammation and organ dysfunction are associated with pancreatic stellate cell (PSC)-to-myofibroblast transformation. Here, we show that IL11 stimulation of PSCs, which specifically express IL11RA in the pancreas, results in transient STAT3 phosphorylation, sustained ERK activation and PSC activation. In contrast, IL6 stimulation of PSCs caused sustained STAT3 phosphorylation but did not result in ERK activation or PSC transformation. Pancreatitis factors, including TGFβ, CTGF and PDGF, induced IL11 secretion from PSCs and a neutralising IL11RA antibody prevented PSC activation by these stimuli. This revealed an important ERK-dependent role for autocrine IL11 activity in PSCs. In mice, IL11 was increased in the pancreas after pancreatic duct ligation, and in humans, IL11 and IL11RA levels were elevated in chronic pancreatitis. Following pancreatic duct ligation, administration of anti-IL11RA to mice reduced pathologic (ERK, STAT, NF-κB) signalling, pancreatic atrophy, fibrosis and pro-inflammatory cytokine (TNFα, IL6 and IL1β) levels. This is the first description of IL11-mediated activation of PSCs, and the data suggest IL11 as a stromal therapeutic target in pancreatitis.
Collapse
Affiliation(s)
- Benjamin Ng
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609, Singapore; (W.-W.L.); (J.T.); (C.X.); (S.A.C.)
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
- Correspondence: (B.N.); (E.A.)
| | - Sivakumar Viswanathan
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Anissa A. Widjaja
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Wei-Wen Lim
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609, Singapore; (W.-W.L.); (J.T.); (C.X.); (S.A.C.)
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Shamini G. Shekeran
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Joyce Wei Ting Goh
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Jessie Tan
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609, Singapore; (W.-W.L.); (J.T.); (C.X.); (S.A.C.)
| | - Fathima Kuthubudeen
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Sze Yun Lim
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Chen Xie
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609, Singapore; (W.-W.L.); (J.T.); (C.X.); (S.A.C.)
| | - Sebastian Schafer
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
| | - Eleonora Adami
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
- Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany
- Correspondence: (B.N.); (E.A.)
| | - Stuart A. Cook
- National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609, Singapore; (W.-W.L.); (J.T.); (C.X.); (S.A.C.)
- Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169857, Singapore; (S.V.); (A.A.W.); (S.G.S.); (J.W.T.G.); (F.K.); (S.Y.L.); (S.S.)
- MRC-London Institute of Medical Sciences, Hammersmith Hospital Campus, London W12 0NN, UK
| |
Collapse
|